

## The Pharmacogenomics Journal

### EDITOR

Julio Licinio, UCLA, USA

### EDITORIAL BOARD

J Azuma, Osaka University, Japan  
E Boerwinkle, University of Texas,  
Houston, USA  
U Brinkmann, Epidauros, Germany  
RGH Cotton, University of Melbourne,  
Australia  
D Flockhart, Georgetown University  
Medical Center, USA  
P Froguel, Institut Pasteur de Lille, France  
LM Furness, Incyte Genomics, UK  
T Gingeras, Affymetrix, USA  
M Hashida, Kyoto University, Japan  
W Kalow, University of Toronto, Canada  
T Klein, Stanford University, USA  
I Kola, Pharmacia, USA  
K Lindpaintner, Roche Genetics,  
Switzerland  
R Long, National Institute of General  
Medical Sciences, USA  
P Nadkarni, Yale University, USA  
D Nickerson, University of Washington,  
USA  
L Peltonen, University of California,  
Los Angeles, USA  
M Polymeropoulos, Novartis, USA  
G Poste, Health Technology Networks,  
USA  
A Rane, Karolinska Institutet, Sweden  
M Ratain, University of Chicago, USA  
AD Roses, GlaxoSmithKline, USA  
MA Rothstein, University of Louisville  
School of Medicine, USA  
JC Venter, The Institute for Genomic  
Research, USA  
R Weinshilboum, Mayo Clinic, USA  
S Weiss, Harvard Medical School, USA  
J Woodcock, Food and Drug  
Administration, USA  
R Wolf, University of Dundee, UK  
M-L Wong, University of California,  
Los Angeles, USA  
A Wright, Western General Hospital, UK

### EDITORIAL OFFICES

The Pharmacogenomics Journal  
Nature Publishing Group  
Specialist Journals Division,  
Houndmills, Basingstoke,  
Hampshire RG21 6XS, UK

and

The Pharmacogenomics Journal  
Nature Publishing Group  
Specialist Journals Division,  
345 Park Avenue South  
New York 10010-1707, USA

ThePharmacogenomicsJournal@nature.com  
<http://www.nature.com/tpj>

## *The Pharmacogenomics Journal*: the official journal of the International Society of Pharmacogenomics (ISP)

*The Pharmacogenomics Journal* (2003) 3, 1. doi:10.1038/sj.tpj.6500165

*The Pharmacogenomics Journal* is now entering its third year and it is now the official journal of the International Society of Pharmacogenomics (ISP). The Society's aims are to foster the development of the field through a cross-disciplinary approach and to reach consensus in areas of common interest in this rapidly developing field.

ISP's first business meeting took place in Paris in October 2002 and we are now planning our first meeting, which will be held in conjunction with the Annual Meeting of the American Society for Human Genetics (ASHG). This will take place in Los Angeles in November 2003. Further announcements will confirm venue and dates. We are currently developing the plans to make that meeting a joint effort between ISP and the Pacific Rim College of Pharmacogenetics. Information about the society can be found at our website, which is currently hosted at <http://www.iop.kcl.ac.uk/Extras/IntSocPg/home/home.htm>. Our plans are to expand this site greatly and create mirror access sites.

What will change in *The Pharmacogenomics Journal* as it becomes ISP's official journal? We will maintain our format and editorial independence, which are crucial to our rapid growth and acceptance by the scientific community. A key factor in the success of a new title, such as ours, is editorial independence and fairness. For this reason, ISP will not be responsible for editorial decisions, which will remain the responsibility of the editor. By making *The Pharmacogenomics Journal* the official journal of the International Society for Pharmacogenomics, we hope to provide a forum to bring together society members and to publish peer-reviewed consensus documents that emerge from the activities of the society. Society members will also get a subscription to the journal at a reduced rate.

We thank our authors and readers for the continued support given to *The Pharmacogenomics Journal*. As we start our third volume we will continue to offer rigorous review, high visibility, and rapid publication. By highlighting our articles in *Nature's* website ([www.nature.com](http://www.nature.com)), particularly in the section [pharmacology@nature.com](mailto:pharmacology@nature.com) (<http://www.nature.com/pharma/>), and by making them available to members of the International Society of Pharmacogenomics, we will ensure that our peer-reviewed and independently edited papers will reach a wide readership. We also stimulate readers to subscribe (free of charge) to our table of contents (TOC) alert service by logging at the following site: [www.nature.com/registration](http://www.nature.com/registration), and completing the registration procedures. Manuscript submissions can be made electronically at the following website: <http://mts-tpj.nature.com/cgi-bin/main.plex>.

Julio Licinio, MD  
UCLA Laboratory of Pharmacogenomics, Email: [licinio@ucla.edu](mailto:licinio@ucla.edu)